Document:

Amendment No. 1 to Line License Agreement

 Exhibit 10.25.1 
 Pages where confidential treatment has been requested are stamped ‘Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,’ and the confidential
section has been marked as follows: [***]. 
 CONFIDENTIAL 
 AMENDMENT NO. 1 
 TO LINE LICENSE AGREEMENT 

between 

Ceres, Inc. 

and 
 The
Texas A&M University System 
 This AMENDMENT NO. 1 to the LINE LICENSE AGREEMENT (“AMENDMENT NO. 1”) is made
and entered into by and between Ceres, Inc., a Delaware corporation with principal offices at Thousand Oaks, California (“LICENSEE”), and The Texas A&M University System of which Texas AgriLife Research (“AGRILIFE”) is a
member, having principal offices in College Station, Texas (“SYSTEM”). 
 WITNESSETH: 

WHEREAS, reference is made to that certain Line License Agreement by and between LICENSEE and SYSTEM dated July 12, 2011 (SYSTEM
Internal Ref. No. L-001038) regarding certain sorghum lines created by SYSTEM ( the “AGREEMENT”); and 

WHEREAS, LICENSEE has evaluated certain sorghum lines from SYSTEM under a Material Transfer and Evaluation Agreement, effective
April 23, 2008; and created certain EXISTING HYBRIDS; and 
 WHEREAS, SYSTEM, through its member Texas AgriLife
Research (“AGRILIFE”), and LICENSEE were parties to a Sponsored Research Agreement dated August 29, 2007 (the “SRA”) and an associated Intellectual Property Rights Agreement dated August 29, 2007 (the “IPRA”),
to which the AGREEMENT makes reference, and have subsequently entered into an Amended and Restated Sponsored Research Agreement dated September 24, 2011, which replaces and supersedes the SRA (the “ARSRA”) as well as an associated
Amended and Restated Intellectual Property Rights Agreement dated September 24, 2011, which replaces and supersedes the IPRA (the “ARIPRA”), relating to rights and obligations of the Parties pertaining to certain sorghum lines; and

 WHEREAS, LICENSEE now desires to commercially utilize certain additional sorghum lines as further described in this AMENDMENT
NO. 1 under license subject to the same terms and conditions as provided in the AGREEMENT. 
 NOW THEREFORE, the Parties hereby
agree to amend the AGREEMENT as follows: 
  

	 	1.	DELETE paragraph 1.01 in its entirety and REPLACE it with a new paragraph 1.01 as follows: 

 

	 	1.01.	“LINE” and “LINES” shall mean one or more, as applicable, of the sorghum lines designated as A/B.05040-08CS6466/6465, A/B.05038-08CS6460/6459,
A/B.05035-CS2WF1CS4WF2 and A/B.05037-08CS6476/6475, which were created by SYSTEM prior to the conduct of the SRA and in which SYSTEM has ownership rights, and new genetic lines or populations developed by LICENSEE through further selection within
the LINES, as distinguished from crossing followed by selection. 

  

	 	2.	DELETE paragraph 1.05 in its entirety and REPLACE it with a new paragraph 1.05 as follows: 

 

	 	1.05	“EXISTING HYBRIDS” shall mean those HYBRIDS designated as EJ 7281, EJ 7282, EJ 7J905, and EJ 7J906 developed and owned by LICENSEE, as contemplated under
Article IX.D.(2) of the ARSRA. 

  

	 	3.	DELETE paragraph 2.02 in its entirety and REPLACE it with a new paragraph 2.02 as follows: 

 

	 	2.02	 Reservation. SYSTEM reserves an irrevocable, worldwide, nonexclusive, royalty-free right to practice the grant made in Article 2.01 under (i),
(ii) and (iii) for research, demonstration and educational purposes only, and not for commercial purposes or for the commercial 

  

					
	L-001038; Amendment No. 1	 	Page 1 of 2	 	 

 CONFIDENTIAL 
  

	 	
benefit of third parties. Notwithstanding the above, SYSTEM reserves the right to use the LINES A/B.05040-08CS6466/6465, A/B.05038-08CS6460/6459, A/B.05035- CS2WF1CS4WF2 and
A/B.05037-08CS6476/6475 in the conduct of research sponsored by any third party subject to its compliance with the provisions of the ARSRA and the ARIPRA, including but not limited to the restrictions on Germplasm Improvement as defined in Article
IV.B.(5) of the ARSRA, when exercising this right. 

  

	 	4.	ADD a new paragraph 3.06 as follows: 

  

	 	3.06	Amendment Fee. In consideration for the addition of LINES by amendment to this Agreement, LICENSEE shall pay a single up-front fee of [***] ($[***]) per LINE added by
amendment. This fee shall be due within fifteen (15) days of execution of each amendment. 

  

	 	5.	Pursuant to paragraph 6.05 of the AGREEMENT, DELETE ANNEX I, INTELLECTUAL PROPERTY RIGHTS in its entirety and REPLACE it with a new ANNEX I, INTELLECTUAL PROPERTY
RIGHTS, attached to this AMENDMENT NO. 1. 

  

	 	6.	DELETE ANNEX II, Royalty Report in its entirety and REPLACE it with a new ANNEX II Royalty Report, attached to this AMENDMENT NO. 1. 

Except as provided herein, all terms and conditions of the AGREEMENT remain unchanged and in full force and effect and this AMENDMENT NO. 1 shall form an
integral part thereof. 
 Terms defined in the AGREEMENT are used herein as therein defined. 

The Effective Date of this AMENDMENT NO. 1 is August 31, 2012. 
 Made in two (2) copies. 
 IN WITNESS WHEREOF, the parties have caused this
AMENDMENT NO. 1 to become effective as of the Effective Date 
  

									
	CERES, INC.	 		 	THE TEXAS A&M UNIVERSITY SYSTEM
			
	 /s/ Michael Stephenson
	 		 	 /s/ Brett Cornwell

	By:	 	Michael Stephenson	 		 	Brett Cornwell
	Title:	 	Vice President of Operations	 		 	Associate Vice Chancellor for Commercialization
	Date:	 	  
	 		 	Date:	 	 8/31/12

				
	 /s/ Paul Kuc
	 		 		 	
	By:	 	Paul Kuc	 		 		 	
	Title:	 	Chief Financial Officer	 		 		 	
	Date:	 	  
	 		 		 	

  

					
	L-001038; Amendment No. 1	 	Page 2 of 2	 	 

 Confidential Treatment Requested and the Redacted Material has been separately filed
with the Commission 

 CONFIDENTIAL 
  

 ANNEX I 

to the LINE LICENSE AGREEMENT 
 between Ceres, Inc. and The Texas A&M University System 

INTELLECTUAL PROPERTY RIGHTS 
  

											
	 LINE/HYBRID
	  	 Application Type
	  	 Application Serial No.
	  	 Country
	  	 Status
	 
	EJ 7281	  	PVP	  	21806.000172/2011-49	  	Brazil	  	 	Application	  
	EJ 7281	  	Utility	  	61/654,251	  	US	  	 	Application	  
	EJ 7281	  	PVP	  	201,200,401	  	US	  	 	Application	  
	EJ 7282	  	PVP	  	21806.000173/2011-93	  	Brazil	  	 	Application	  
	EJ 7282	  	Utility	  	61/654,240	  	US	  	 	Application	  
	EJ 7282	  	PVP	  	201,200,402	  	US	  	 	Application	  

  

					
	L-001038; Amendment No. 1	 	 	 	ANNEX II-Page 1 of 4

 CONFIDENTIAL 
  

 ANNEX II 

to the LINE LICENSE AGREEMENT 
 between Ceres, Inc. and The Texas A&M University System 
 Royalty
Report 
 Date of report: [X] 
 BUSINESS YEAR of report: [X] 
 HYBRID: EJ 7281 

LINE(s): 
 A/B.05040-08CS6466/6465

  

									
	 Royalty Calculation

	 	  	 Base Rate
	 	 OTHER

CONTRIBUTIONS*
	 	 AGRILIFE
 GENETIC
 CONTRIBUTION
	 	 Royalty

Rate

	NET SALES	  	[***]%	 	0%	 	50%	 	[***]%
	LICENSE INCOME	  	[***]%	 	0%	 	50%	 	[***]%
				
	 *OTHER CONTRIBUTIONS
	 	 	 	 	 	 
	Name of Contribution	  	Deduction %	 		 		 	
	None	  	None	 		 		 	

 Total revenue: [$X] 
 Additional deductions for NET SALES from Article 1.12(f): None 
 NET SALES for BUSINESS YEAR: [$X]

 Royalties due on NET SALES: [$X] 

LICENSE INCOME for BUSINESS YEAR: [$X] 

Royalties due on LICENSE INCOME: [$X] 

  

					
	L-001038; Amendment No. 1	 	 	 	ANNEX II-Page 1 of 4

 Confidential Treatment Requested and the Redacted Material has been separately filed
with the Commission 

 CONFIDENTIAL 
  

 HYBRID: EJ 7282 
 LINE(s): 
 A/B.05038-08CS6460/6459 

 

									
	 Royalty Calculation

	 	  	 Base Rate
	 	 OTHER

CONTRIBUTIONS*
	  	 AGRILIFE
 GENETIC
 CONTRIBUTION
	  	 Royalty

Rate

	Net Sales	  	[***]%	 	0%	  	50%	  	[***]%
	License Income	  	[***]%	 	0%	  	50%	  	[***]%
				
	 *OTHER CONTRIBUTIONS
	 		  		  	
	Name of Contribution	  	Deduction %	 		  		  	
	None	  	None	 		  		  	

 Total revenue: [$X] 
 Additional deductions for NET SALES from Article 1.12(f): None 
 NET SALES for BUSINESS YEAR: [$X]

 Royalties due on NET SALES: [$X] 

LICENSE INCOME for BUSINESS YEAR: [$X] 

Royalties due on LICENSE INCOME: [$X] 

  

					
	L-001038; Amendment No. 1	 	 	 	ANNEX II-Page 1 of 4

 Confidential Treatment Requested and the Redacted Material has been separately filed
with the Commission 

 CONFIDENTIAL 
  

 HYBRID: EJ 7J906 
 LINE(s): 
 A/B.05035-CS2WF1CS4WF2 

 

									
	 Royalty Calculation

	 	  	 Base Rate
	 	 OTHER

CONTRIBUTIONS*
	  	 AGRILIFE
 GENETIC
 CONTRIBUTION
	  	 Royalty

Rate

	Net Sales	  	[***]%	 	0%	  	50%	  	[***]%
	License Income	  	[***]%	 	0%	  	50%	  	[***]%
				
	 *OTHER CONTRIBUTIONS
	 		  		  	
	Name of Contribution	  	Deduction %	 		  		  	
	None	  	None	 		  		  	

 Total revenue: [$X] 
 Additional deductions for NET SALES from Article 1.12(f): None 
 NET SALES for BUSINESS YEAR: [$X]

 Royalties due on NET SALES: [$X] 

LICENSE INCOME for BUSINESS YEAR: [$X] 

Royalties due on LICENSE INCOME: [$X] 

  

					
	L-001038; Amendment No. 1	 	 	 	ANNEX II-Page 1 of 4

 Confidential Treatment Requested and the Redacted Material has been separately filed
with the Commission 

 CONFIDENTIAL 
  

 HYBRID: EJ 7J905 
 LINE(s): 
 A/B.05037-08CS6476/6475 

 

									
	 Royalty Calculation

	 	  	 Base Rate
	 	 OTHER

CONTRIBUTIONS*
	  	 AGRILIFE
 GENETIC
 CONTRIBUTION
	  	 Royalty

Rate

	Net Sales	  	[***]%	 	0%	  	50%	  	[***]%
	License Income	  	[***]%	 	0%	  	50%	  	[***]%
				
	 *OTHER CONTRIBUTIONS
	 		  		  	
	Name of Contribution	  	Deduction %	 		  		  	
	None	  	None	 		  		  	

 Total revenue: [$X] 
 Additional deductions for NET SALES from Article 1.12(f): None 
 NET SALES for BUSINESS YEAR: [$X]

 Royalties due on NET SALES: [$X] 

LICENSE INCOME for BUSINESS YEAR: [$X] 

Royalties due on LICENSE INCOME: [$X] 

  

Confidential Treatment Requested and the Redacted Material has been separately filed with the CommissionSchedule 7 to Master Research Agreement

 Exhibit 10.26.1 
 Pages where confidential treatment has been requested are stamped ‘Confidential Treatment Requested and the Redacted Material has been separately filed with the Commission,’ and the confidential
section has been marked as follows: [***]. 
 SCHEDULE 7 (BREEDING) 

THIS SCHEDULE is made this 1st day of August 2012; 
  

			
	BETWEEN	  	CERES, INC., a Delaware corporation, having its principal place of business at 1535 Rancho Conejo Blvd., Thousand Oaks, CA 91320 (“CERES”)
and
		
		  	THE SAMUEL ROBERTS NOBLE FOUNDATION INCORPORATED, an Oklahoma non-profit corporation, having its principal place of business at 2510 Sam Noble Parkway, Ardmore, Oklahoma 73401
(“NOBLE”);

 WHEREAS, CERES and NOBLE have entered into a Master Research Agreement (“MRA”), dated 19 May 2006,
which allows for the undertaking of RESEARCH PROJECTS pursuant to SCHEDULES, these terms being defined in the MRA; and 
 THEREFORE, the
parties have agreed to undertake the following RESEARCH PROJECT as defined herein on the following terms and conditions: 
 GENERAL

 A. Unless otherwise specified herein, the terms of the MRA shall apply to this SCHEDULE. 

B. In the event of any difference between the terms of this SCHEDULE and the MRA, then the terms of this SCHEDULE shall prevail. 

RESEARCH PROJECT TITLE: Switchgrass Cultivar Development 

 

	1.	PROPOSAL OBJECTIVE: Develop commercial switchgrass cultivars for use in bioenergy and forage cropping systems via conventional breeding and developing molecular
[***] tools. 

 1.1 Testing of Experimental [***] Cultivars and [***] 

1.2 Building Populations for Use as [***] for Future [***] Parents 

 

	2.	WORK TO BE UNDERTAKEN: 

  

	 	See	RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE). 

  

	3.	DETAILED WORKPLAN: 

  

	 	See	RESEARCH AND DEVELOPMENT PLAN (Attachment A to this SCHEDULE). 

  

	4.	LOCATION OF WORK: 

NOBLE Work: 
 All NOBLE laboratory and greenhouse facilities and properties will be conducted at its Ardmore and Burneyville locations, as well as current plots at UGA farms in Georgia. 

CERES Work: 
 College Station Research Center, TX 

  

			
	CERES-NOBLE Schedule Breeding-Genomics	 	Page 1 of 8

 Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission 

	5.	PRINCIPAL SCIENTIFIC STAFF: 

 Joe Bouton (NOBLE) 
 Charlie Brummer (NOBLE) 

Malay Saha (NOBLE) 
 Jeff Gwyn (CERES) 
 Charlie Rodgers (CERES) 

Tim Swaller (CERES) 
  

	6.	MAJOR CONSUMABLES/LIVESTOCK TO BE PURCHASED: 

 None 
  

	7.	REPORTS: 

 All reports
shall be delivered to the MANAGEMENT COMMITTEE on or before the required delivery dates for the same. 
 NOBLE will deliver at
each quarterly MANAGEMENT COMMITTEE meeting (or annual meeting, as the case may be): 
  

	 	•	 	 Annual Report (compilation of slide presentations and quarterly minutes) (annual meeting). 

 

	 	•	 	 Quarterly status update and FTE breakout based on attached planning document. 

 

	 	•	 	 Actual spending relative to budget. 

  

	 	•	 	 INTELLECTUAL PROPERTY generated during the period. 

  

	 	•	 	 Copies of slide presentations summarizing research progress (template attached as Attachment B to this SCHEDULE). 

 

	 	•	 	 Phenotypic and genotypic information collected on different populations evaluated in this collaboration. 

Additional information, if not specifically included in the delivered information (above), shall be delivered (or later provided, wherein
the delivering party shall indicate the delivery method and time) as supporting information at the related quarterly meeting, if available: 
 NOBLE will deliver: 
  

	 	•	 	 Copies of field or greenhouse books and records 

  

	 	•	 	 Copies of raw field trial data 

  

	 	•	 	 Raw [***] and plant phenotypic data 

  

	 	•	 	 [***], seed, dry tissue, and [***] from different populations as required 

CERES will deliver: 
  

	 	•	 	 [***] information such as sequence specific to agreed phenotypic association utilized in the program 

 

	8.	COMMENCEMENT/TERMINATION: 

Commencement: August 1, 2012 
 Termination: July 31, 2014 

  

			
	CERES-NOBLE Schedule Breeding-Genomics	 	Page 2 of 8

 Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission 

	9.	REPORT PREPARATION: 

 Joe
Bouton (NOBLE) 
 Charlie Brummer (NOBLE) 
 Malay Saha (NOBLE) 
 Jeff Gwyn (CERES) 

Charlie Rodgers (CERES) 
 Tim Swaller (CERES) 
  

	10.	REPORT DATES: 

Quarterly reports and information: Due at quarterly meetings of the MANAGEMENT COMMITTEE per the MRA (e.g., March, June, September,
December). 
  

	11.	ASSETS: 

 Not applicable

  

	12.	INSURANCE: 

 Not
applicable 
  

	13.	CONTRIBUTION TO JOINT INTELLECTUAL PROPERTY: 

 Controlled by MRA 
  

	14.	SPECIAL CONDITIONS: 

Not applicable 
  

	15.	INTELLECTUAL PROPERTY RIGHTS: 

  

	 	15.1	NOBLE Background Intellectual Property: 

  

	 	•	 	 Breeding populations, phenotypes and [***] on these populations 

 

	 	15.2	CERES Background Intellectual Property: 

  

	 	•	 	 Sequences from switchgrass and other species 

  

	 	•	 	 Gene trait association information 

  

	 	•	 	 Patent applications covering any of the foregoing 

  

	16.	SUBCONTRACTORS AND LOCATIONS: 

 Not applicable 
  

	17.	PROVISIONS FOR EARLY TERMINATION: 

 This SCHEDULE does not terminate automatically upon termination of the MRA. 

  

			
	CERES-NOBLE Schedule Breeding-Genomics	 	Page 3 of 8

 Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission 

 This SCHEDULE shall expire pursuant to the terms set forth in this SCHEDULE, unless extended
by the mutual agreement of the parties, or unless sooner terminated in accordance with the following provisions of this Paragraph: 
 (a) mutual, written agreement of the parties; 
 (b) failure of one
party to satisfy its material obligations under this Agreement, and such party subsequently fails to cure such failure(s) within (i) thirty (30) days for failures to remit payment for amounts due under this Agreement and (ii) ninety
(90) days for all other obligations in each case after receipt of written notice from the non-breaching party specifying such failure(s); 
 (c) one hundred eighty (180) days’ prior written notice of termination by either CERES or NOBLE to the other party in case either the terminating party or the other party ceases substantially
all activities in the COLLABORATION CROPS; 
 (d) NOBLE will have the right to terminate this Agreement
unilaterally with thirty (30) days’ written notice to CERES, (i) if CERES seeks protection under any bankruptcy, insolvency, receivership, trust, deed, creditors arrangement or comparable proceeding or if any such proceeding is
instituted against CERES (and not dismissed within one hundred twenty (120) days); (ii) in case of dissolution or winding up of CERES (excluding any situation where all or substantially all of CERES’ assets, stock or business to which
this Agreement relates are acquired by a third party (whether by sale, acquisition, merger, operation of law or otherwise)); or (iii) with one hundred twenty (120) days’ written notice to CERES, if the institutional mission, purpose
or structure of NOBLE would change substantially and adversely affect NOBLE’S ability to satisfy its obligations hereunder; or 
 (e) CERES will have the right to terminate this Agreement unilaterally: (i) with thirty (30) days’ written notice to NOBLE if Dr. Joe Bouton and Dr. Charlie Brummer cease to be
associated with NOBLE and the research activities associated with this SCHEDULE, and NOBLE has not replaced him within one hundred twenty (120) days by a person reasonably acceptable to CERES; (ii) with ninety (90) days’ written
notice to NOBLE, if the institutional mission, purpose or structure of NOBLE would change substantially; or (iii) with one (1) year’s written notice to NOBLE, if CERES has compelling business reasons to cease the collaboration.

  

	18.	USE AND COMMERCIALIZATION RIGHTS: 

 Controlled by MRA 
  

	19.	CONFIDENTIALITY/PUBLICATION: 

 Controlled by MRA 

  

			
	CERES-NOBLE Schedule Breeding-Genomics	 	Page 4 of 8

	20.	FUNDING APPROVED: 

 Projected Budget
(per year from CERES): 
  

									
	 Personnel
	  	Year 1	 	  	Year 2	  	Sub-totals
	 Res. Assistant + Fringe Benefits
	  	$	[***]	  	  	$[***]	  	$[***]
		  	  
	  
	 	  	  
	  	  

	 Hourly Labor
	  	$	[***]	  	  	$[***]	  	$[***]
		  	  
	  
	 	  	  
	  	  

	 Sub-total (Salary + Benefits)
	  	$	[***]	  	  	$[***]	  	$[***]
		  	  
	  
	 	  	  
	  	  

	 Travel
	  	$	[***]	  	  	$[***]	  	$[***]
	 Supplies
	  	$	[***]	  	  	$[***]	  	$[***]
		  	  
	  
	 	  	  
	  	  

	 Total Direct Costs
	  	$	[***]	  	  	$[***]	  	$[***]
		  	  
	  
	 	  	  
	  	  

	 Indirect ( 50% of Direct)
	  	$	[***]	  	  	$[***]	  	$[***]
		  	  
	  
	 	  	  
	  	  

	 Total
	  	$	[***]	  	  	$[***]	  	$[***]
		  	  
	  
	 	  	  
	  	  

 Budget justification: 
 Salaries:
 The Research Assistant and hourly labor will provide additional
hands for the field evaluations, harvesting, and greenhouse work needed to complete the project. Fringe benefits are calculated at [***]% to include FICA and health insurance and thrift for the Research Assistant. A five percent fixed salary
increase is requested for the second year. Hourly labor support is requested both years for additional help with fieldwork and data collection. 
 Travel: 
 Travel funds are requested to allow the main scientific personnel
to travel to the off-site research plots in Georgia. 
 Supplies: 

$[***] per year is requested for general supplies for field and greenhouse studies. 

Billing Schedule: Invoices will be sent by NOBLE to CERES for actual expenses from the previous period on the last day of the first month
following the close of each quarter, not to exceed the total amounts per year as specified above. 

  

			
	CERES-NOBLE Schedule Breeding-Genomics	 	Page 5 of 8

 Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission 

 IN WITNESS THEREOF this SCHEDULE has been executed on the date hereinbefore entered. 

CERES, INC. 
  

					
	 /s/ Michael Stephenson
	 	8/15/12
	By:	 	Michael Stephenson	 	Date
		 	Vice President of Operations	 	
		
	 /s/ J. Jefferson Gwyn
	 	8/7/12
	By:	 	J. Jefferson Gwyn, PhD	 	Date
		 	Vice President, Breeding & Genomics	 	

 THE SAMUEL ROBERTS NOBLE FOUNDATION, INC. 

 

					
	 /s/ Steven Rhines
	 	30 July 2012
	By:	 	Steven Rhines	 	Date
		 	Vice President, General Counsel	 	

  

			
	CERES-NOBLE Schedule Breeding-Genomics	 	Page 6 of 8

 ATTACHMENT A 
 RESEARCH AND DEVELOPMENT PLAN 
 CERES-NOBLE SCHEDULE 7 (BREEDING 2012-2014)

 Goal 1: Testing of Experimental [***] Cultivars and [***] 

The following experimental [***] developed during the previous schedules were established in performance trials at both Ardmore, OK and Athens, GA during
2010. They were harvested for yield during 2011 and as part of this current schedule, and will be harvested again during 2012 and 2013. The best performing cultivars will be identified based on their multi-location yields and performance and
pre-breeder seed from the superior [***] cultivars, and clonal [***] that gave the best [***] and will be stored or transferred to Ceres. 
  

	
	 Entry

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	 EG1101

	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	[***]
	 EG1102

 In 2011, the following experimentals were likewise established and harvested at Ardmore. Certain designated entries were
also being evaluated in UGA Athens, along with other UGA 

  

			
	CERES-NOBLE Schedule Breeding-Genomics	 	Page 7 of 8

 Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission 

 
entries. In addition, all entries from this trial, plus the 2010 trial shown above, were established by Ceres at College Station, TX. These trials will be harvested during the 2012 and 2013
growing seasons. Again, the best performing cultivars will be identified based on their multi-location yields and performance and seed from the superior [***] cultivars and clonal [***] that gave the best [***] and will be stored or transferred to
Ceres. 
  

			
	 Entry
	  	 Entry

	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	[***]
	[***]	  	EG1101
	[***]	  	EG1102
	[***]	  	
	[***]	  	

 Goal 2: Building Populations for Use as [***] for Future [***] Parents: 

Work to date: 
 This is an extension of
the CERES-NOBLE Schedule 5. 
 Proposed work: 
 The [***] from the [***] by [***] crosses were established in the field at Burneyville, OK in May 2012 and will be evaluated for yield and performance during 2012 and 2013. Since phenotyping will be
accomplished during the proposed work, it is also possible that a project could result based on these [***]. Noble could collect plant tissue and Ceres could conduct the actual [***]. The feasibility of this project can be determined at a later date
by the MANAGEMENT COMMITTEE. 

  

			
	CERES-NOBLE Schedule Breeding-Genomics	 	Page 8 of 8

 Confidential Treatment Requested and the Redacted Material has been separately filed with the
Commission

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00210-of-00352.parquet"}]]